Wuxi Clinical Development Services (Shanghai) Co., Ltd.

Primary objective: To evaluate the pharmacokinetics (PK) of single and multiple doses of paltusotine in the Chinese population; Secondary objective: To evaluate the safety of paltusotine in the Chinese population.

Primary objective: To evaluate the safety and tolerability of BBT-401-1S in healthy Chinese adult volunteers after single and multiple oral administrations of different doses. Secondary objective: To evaluate the pharmacokinetic characteristics of BBT-401-1S in healthy Chinese adult volunteers after single and multiple oral administrations of different doses.

Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of 10 mg of the test preparation atomoxetine hydrochloride capsule (Nichi-lko Pharmaceutical Co. Ltd.) and the reference preparation atomoxetine hydrochloride capsule (trade name: Zestda®, LILLY DEL CARIBE Inc.) in healthy Chinese subjects on an empty stomach and after a high-fat, high-calorie meal, to evaluate the bioequivalence of the test preparation and the reference preparation, and to provide a basis for the registration and clinical use of the drug. Secondary objective: To evaluate the safety of a single oral dose of 40 mg of the test preparation atomoxetine hydrochloride capsule and 10 mg of the reference preparation atomoxetine hydrochloride capsule in healthy Chinese subjects.